The World Psychiatric Association (WPA) unites 147 psychiatric societies across 123 countries, supporting over 250,000 psychiatrists and fostering specialized collaborations in the field of psychiatry.
We are exhibiting at the 26th World Congress of Psychiatry 2026
Visit us in our booth to discuss white blood cell monitoring in psychiatry
Clozapine is considered gold standard for treating TRS (treatment-resistant schizophrenia) but is greatly underused in most regions. Clozapine treatment requires mandatory blood monitoring of absolute neutrophil count.
The HemoCue® WBC DIFF System brings the unique possibility to test and receive reliable white cell count with a 5-part differential right at the point of care, increasing the likelihood of successful monitoring while creating a safe space for the patient.
Want to learn more about how point-of-care testing can enhance your treatment plans for patients with TRS?
Date: 23–26 of September
Location: Stockholm
Booth: Nr. 8
See you at the World Congress of Psychiatry 2026!
Want to learn more about the impact of point-of-care white blood cell testing in psychiatric care?
Access supporting materials to learn more about compliant clozapine treatment and the HemoCue® WBC DIFF System
Download the WBC DIFF customer story
Download the WBC DIFF System product sheet
Download the WBC DIFF System sales sheet
Download the WBC DIFF white paper
Lead form
Please fill out the form below and your request will be forwarded to a HemoCue representative.
